Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
RR 1.05 [0.52, 2.11]
728 participants
Low
Clinical malaria · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.54 [0.43, 0.67]
728 participants
High
Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertensive disorders of pregnancy · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy.
It is very uncertain whether oral anti‐diabetic pharmacological therapies changes hypertensive disorders of pregnancy ‐ (any type) compared with placebo ‐ maternal outcomes (very low certainty).
1 finding from 1 review
Death or serious morbidity composite · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal hypoglycaemia · Infants of women diagnosed with gestational diabetes
It is very uncertain whether oral anti‐diabetic pharmacological therapies changes neonatal hypoglycaemia compared with placebo ‐ neonatal outcomes (very low certainty).
1 finding from 1 review
Adiposity (neonate, child, adult) ‐ not measured · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetes · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurosensory disability in later childhood ‐ not measured · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caearean section · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy.
It is very uncertain whether oral anti‐diabetic pharmacological therapies changes caearean section compared with placebo ‐ maternal outcomes (very low certainty).
1 finding from 1 review
Development of type 2 diabetes ‐ not measured · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found